Next Article in Journal
Nanoparticles to Improve the Efficacy of Peptide-Based Cancer Vaccines
Next Article in Special Issue
Rafoxanide Induces Immunogenic Death of Colorectal Cancer Cells
Previous Article in Journal
Functional and Clinical Impact of CircRNAs in Oral Cancer
Open AccessReview

Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death

1
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz 5165665811, Iran
2
Department of Immunology and Microbiology, Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil 5618985991, Iran
3
Research & Development Lab, BSD Robotics, 4500 Brisbane, Australia
4
Department of Cancer and Inflammation Research, Institute for Molecular Medicine, University of Southern Denmark, 5230 Odense, Denmark
5
IRCCS Istituto Tumori “Giovanni Paolo II” of Bari, 70124 Bari, Italy
6
Department of Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro”, 70124 Bari, Italy
7
Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran
*
Authors to whom correspondence should be addressed.
The first two authors contributed equally to this work.
Cancers 2020, 12(4), 1047; https://doi.org/10.3390/cancers12041047
Received: 12 March 2020 / Revised: 8 April 2020 / Accepted: 17 April 2020 / Published: 23 April 2020
(This article belongs to the Special Issue Immunogenic Cell Death and Immunotherapy in Cancers)
Cell death resistance is a key feature of tumor cells. One of the main anticancer therapies is increasing the susceptibility of cells to death. Cancer cells have developed a capability of tumor immune escape. Hence, restoring the immunogenicity of cancer cells can be suggested as an effective approach against cancer. Accumulating evidence proposes that several anticancer agents provoke the release of danger-associated molecular patterns (DAMPs) that are determinants of immunogenicity and stimulate immunogenic cell death (ICD). It has been suggested that ICD inducers are two different types according to their various activities. Here, we review the well-characterized DAMPs and focus on the different types of ICD inducers and recent combination therapies that can augment the immunogenicity of cancer cells. View Full-Text
Keywords: immunogenic cell death; DAMPs; combination therapy immunogenic cell death; DAMPs; combination therapy
Show Figures

Figure 1

MDPI and ACS Style

Asadzadeh, Z.; Safarzadeh, E.; Safaei, S.; Baradaran, A.; Mohammadi, A.; Hajiasgharzadeh, K.; Derakhshani, A.; Argentiero, A.; Silvestris, N.; Baradaran, B. Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death. Cancers 2020, 12, 1047.

AMA Style

Asadzadeh Z, Safarzadeh E, Safaei S, Baradaran A, Mohammadi A, Hajiasgharzadeh K, Derakhshani A, Argentiero A, Silvestris N, Baradaran B. Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death. Cancers. 2020; 12(4):1047.

Chicago/Turabian Style

Asadzadeh, Zahra; Safarzadeh, Elham; Safaei, Sahar; Baradaran, Ali; Mohammadi, Ali; Hajiasgharzadeh, Khalil; Derakhshani, Afshin; Argentiero, Antonella; Silvestris, Nicola; Baradaran, Behzad. 2020. "Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death" Cancers 12, no. 4: 1047.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop